Peripheral artery disease

Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update

Retrieved on: 
Friday, March 22, 2024
Diagnosis, Research, U.S. FDA, Peripheral artery disease, Infection, Patent, Buddha's hand, Evaluation, PAD, Journal, Sale, University, Doctor of Philosophy, Efficacy, Priority review, Regenerative medicine, Clinical trial, Trial of the century, Vascular surgery, HAV, Hospital, Injury, Nationwide Children's Hospital, HUMA, FACS, Amputation, Food, FDA, Defense, BLA, PDUFA, Pharmaceutical industry

DURHAM, N.C., March 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced financial results for the fourth quarter and year ended December 31, 2023 and highlighted recent corporate accomplishments in advancing the investigational Human Acellular Vessel (HAV) closer to planned U.S. market launch.

Key Points: 
  • There was no revenue for either the fourth quarter of 2023 or the fourth quarter of 2022, and there was no revenue for the year ended December 31, 2023.
  • Research and development expenses were $20.2 million for the fourth quarter of 2023, compared to $15.0 million for the fourth quarter of 2022, and were $76.6 million for the year ended December 31, 2023, compared to $63.3 million for the year ended December 31, 2022.
  • General and administrative expenses were $6.0 million for the fourth quarter of 2023, compared to $5.8 million for the fourth quarter of 2022, and were $23.5 million for the year ended December 31, 2023, compared to $22.9 million for the year ended December 31, 2022.
  • The 2023 increases in net loss resulted from the non-cash remeasurement of the contingent earnout liability, and operating expense increases, described above.

Johnson & Johnson to Acquire Shockwave Medical

Retrieved on: 
Friday, April 5, 2024
Research, Medical Devices, Health Technology, Cardiology, Biotechnology, Other Health, Health, Pharmaceutical, Science, Cardiovascular disease, Worldwide, Growth, Peripheral artery disease, Coronary artery disease, Johnson & Johnson, Patient, PAD, JNJ, Perella Weinberg Partners, Acquisition, Electrophysiology, Death, IVL, Medtech, Ventricular fibrillation, European, PCI, Artery, Laminar, Stenosis, Hand, Physician, Percutaneous coronary intervention, CAD, Pharmaceutical industry

Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired.

Key Points: 
  • Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired.
  • The transaction is expected to accelerate revenue growth for both Johnson & Johnson and Johnson & Johnson MedTech.
  • Delivers immediate operational accretion: The transaction will be accretive to operating margin for both Johnson & Johnson and Johnson & Johnson MedTech.
  • Under the terms of the agreement, Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash through a merger of Shockwave with a wholly owned Johnson & Johnson subsidiary.

Global Balloon Catheter Market Analysis Report 2023-2030: Minimally Invasive Solutions and Age-Associated Cardiovascular Problems Drive Demand - ResearchAndMarkets.com

Retrieved on: 
Friday, March 22, 2024
Medical Supplies, Medical Devices, Health, Surgery, Cardiology, Biotechnology, Coronary artery disease, Balloon catheter, Neurology, Prevalence, Headache, Urbanization, Blood, Peripheral artery disease, Urology, Angioplasty, Nylon, Hospital, Restenosis, Research, Splenic infarction, Telehealth, Heart, Stroke, Artery, Safety, Prognosis, Catheter, FDA, Artificial intelligence, CAD, Ageing, Medical device

The "Global Balloon Catheter Market, Size, Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Balloon Catheter Market, Size, Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The growing prevalence of age-associated cardiovascular problems propels balloon catheter demand, significantly increasing the medical device market and enhancing the care of growing older populations globally.
  • Offering minimally invasive alternatives to conventional surgeries, balloon catheters lead to faster recuperation instances, decreased dangers, and progressed patient effects, driving market increase towards minimally invasive tactics.
  • By product type, the Global Balloon Catheter Market is divided into Normal Balloon Catheter, Drug Eluting Balloon Catheter, Cutting Balloon Catheter, Scoring Balloon Catheter, Stent Graft Balloon Catheter, and Others.

Elixir Medical Receives FDA Breakthrough Device Designation for the DynamX BTK System for Use in the Treatment of Chronic Limb-Threatening Ischemia Resulting From Below-The-Knee Arterial Disease

Retrieved on: 
Thursday, March 21, 2024
Medical Devices, Hospitals, Clinical Trials, Cardiology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Elixir, Peripheral artery disease, CLTI, Medicine, Risk, Patient, PAD, Mortality, Motion, Life, BTK, Amputation, Marketing, FDA, Circulant matrix, Food, Pharmaceutical industry

The DynamX Bioadaptor platform is a medical technology designed to establish the new standard of care for vascular interventions.

Key Points: 
  • The DynamX Bioadaptor platform is a medical technology designed to establish the new standard of care for vascular interventions.
  • "The Bioadaptor platform was developed to transform treatment of coronary and peripheral artery disease,” said Motasim Sirhan, CEO at Elixir Medical.
  • “We appreciate the FDA recognition of our innovation for treating the CLTI population with BTK disease and its potential impact on the patients suffering from vascular disease.”
    The FDA Breakthrough Device Designation accelerates the review process for novel technologies designed to address an unmet medical need.
  • Devices that receive breakthrough designation must meet rigorous standards for device safety and effectiveness in order to be authorized for marketing.

Iliac Stent Market Size, Share & Trends Analysis Report 2024: A USD 1.53 Billion Market by 2030, Projected to Grow at a CAGR of 5.8% from 2024 to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Health, Surgery, Medical Devices, Hospital, NCBI, Obesity, NMPA, Growth, Prevalence, Peripheral artery disease, Getinge Group, Incidence, Patient, Evaluation, PAD, Plaque, Google Images, National Medical Products Administration, Iliac artery, USD, Marketing, Pharmaceutical industry

The global iliac stent market size is expected to reach USD 1.53 billion by 2030, projected to grow at a CAGR of 5.8% from 2024 to 2030.

Key Points: 
  • The global iliac stent market size is expected to reach USD 1.53 billion by 2030, projected to grow at a CAGR of 5.8% from 2024 to 2030.
  • Furthermore, the growing prevalence of peripheral artery disease (PAD) is expected to propel iliac stents market growth.
  • In 2023, North America held the largest share in the iliac stents market, with a revenue share of 43.7%.
  • Hospitals serve as referral centers where patients receive comprehensive care, including diagnostic imaging, medical management, and interventional procedures like iliac stent placement

Global Guidewires (Nitinol, Stainless Steel, Others) Market Report 2024: Analysis & Forecasts 2019-2022 and 2023-2029 - Minimally Invasive Techniques Expand, Boosting Guidewire Utilization - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2024
General Health, Health, Medical Supplies, Medical Devices, Disease, PVI, Friction, ERCP, Coronary artery disease, Conditional sentence, Bacteria, Epidemiology, Specialization, Risk, Investment, Infection, Patient safety, USD, Surgery, Non-communicable disease, Cardiovascular disease, Fungal infection, Obesity, Biotechnology, Peripheral artery disease, Porter's five forces analysis, Diabetes, Chlorhexidine, World Health Organization, Safety, Fatigue, Hypertension, Cardiology, Neurology, Urology, Prevalence, Death, PCI, Diagnosis, Arrhythmia, Temperature, Growth, Incidence, Anatomy, SWOT, Mortality, Stainless steel, WHO, Nickel titanium, Physician, Medical imaging

Guidewires Market is being propelled increasing prevalence of cardiovascular diseases, technological advancements in guidewire design and materials, rising demand for minimally invasive procedures, and expanding healthcare infrastructure in developing economies.

Key Points: 
  • Guidewires Market is being propelled increasing prevalence of cardiovascular diseases, technological advancements in guidewire design and materials, rising demand for minimally invasive procedures, and expanding healthcare infrastructure in developing economies.
  • As the prevalence of risk factors such as obesity, diabetes, and hypertension increase, so does the incidence of cardiovascular diseases.
  • Guidewires are essential tools in percutaneous coronary interventions (PCI), peripheral vascular interventions (PVI), and electrophysiology procedures, driving the demand for guidewires.
  • The increasing prevalence of chronic diseases worldwide drives the demand for guidewires by necessitating minimally invasive interventions for diagnosis and treatment.

Johnson & Johnson to Showcase its Broad Scientific Leadership and Latest Innovations to Combat Cardiovascular Disease at ACC.24

Retrieved on: 
Thursday, April 4, 2024
Cardiology, Abstract, Rivaroxaban, Cardiovascular disease, Worldwide, Peripheral artery disease, Health, Atrial fibrillation, Risk, Patient, Knowledge, PAD, Stroke, Research, Death, Statistics, American College, Danger, Johnson & Johnson, Acute coronary syndrome, Pharmaceutical industry

NEW BRUNSWICK, N.J., April 4, 2024 /PRNewswire/ -- Johnson & Johnson announced today that clinical and real-world evidence from its cardiovascular portfolio will be featured at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) taking place April 6-8, 2024, in Atlanta, Georgia. Eleven abstracts, including five oral presentations, will showcase data from Company-sponsored studies demonstrating therapeutic benefit of breakthrough medicines, such as XARELTO® (rivaroxaban), and interventional technologies, such as those from Abiomed® and Biosense Webster®, to help treat cardiovascular diseases, including atrial fibrillation (AF) and peripheral artery disease (PAD).

Key Points: 
  • "At ACC.24, we look forward to sharing the latest research and innovation from our broad portfolio, including XARELTO®, to equip clinicians and researchers with knowledge and insights that can help transform cardiovascular care for all."
  • Johnson & Johnson is committed to elevating the standard of care in cardiovascular diseases and unlocking the potential of medicines and solutions of tomorrow.
  • Several data presentations at ACC.24 demonstrate how the Company is improving outcomes for people living with cardiovascular disease, including older adults and other patient populations often considered hard to treat.
  • The data we're presenting at ACC.24 demonstrate how we're continuing to deliver on our commitment," said Tim Schmid, Executive Vice President and Worldwide Chairman, Johnson & Johnson MedTech.

Endologix Appoints Mike Mathias as Chief Commercial Officer

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, General Health, Medical Devices, Health, Pharmaceutical, TAVR, MD, Strategic planning, MBA, Percutaneous aortic valve replacement, University, Vascular disease, Peripheral artery disease, Organization, Medtronic, EVAR, Endovascular aneurysm repair

Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced the appointment of Mike Mathias as the company’s Chief Commercial Officer, effective immediately.

Key Points: 
  • Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced the appointment of Mike Mathias as the company’s Chief Commercial Officer, effective immediately.
  • With a distinguished 30-year career in leading commercial organizations within the cardiovascular arena, Mike brings a wealth of experience and a proven track record of success to Endologix.
  • Mike is uniquely qualified to lead our global commercial team and continue the strategic development of our commercial plans.
  • In response to his new role, Mike Mathias shared, "Joining Endologix at such a critical juncture is an honor.

BD to Present Next Installment of BD Innovates Series: Spotlight on Peripheral Vascular Disease

Retrieved on: 
Monday, February 12, 2024
BDX, Peripheral artery disease, Computer data storage

FRANKLIN LAKES, N.J., Feb. 12, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present the next installment of its BD Innovates series — which will highlight BD solutions that help clinicians treat Peripheral Vascular Disease — on Monday, February 26, 2024, at 3:00 PM Eastern Time.

Key Points: 
  • FRANKLIN LAKES, N.J., Feb. 12, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present the next installment of its BD Innovates series — which will highlight BD solutions that help clinicians treat Peripheral Vascular Disease — on Monday, February 26, 2024, at 3:00 PM Eastern Time.
  • The BD Innovates series spotlights BD's innovation, products and pipeline in support of its BD 2025 Strategy, with this installment highlighting the Peripheral Vascular Disease platform within the BD Peripheral Intervention business unit.
  • The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com.
  • A replay of the event will be available on the same webpage following its conclusion.

Sensome Announces Initiation of Clinical Trial Assessing Its Tissue Microsensor Technology in Peripheral Artery Disease

Retrieved on: 
Monday, February 12, 2024
Other Health, Research, Radiology, Medical Devices, Clinical Trials, Science, Surgery, Cardiology, FDA, Other Science, Health, Diabetes, Physician, Clinical trial, Hospital, PAD, Patient, Trial of the century, Peripheral artery disease, Stroke, Medical imaging

Sensome, the company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today enrollment of the first patients into a feasibility clinical study using the Clotild® Smart Guidewire in peripheral artery disease (PAD).

Key Points: 
  • Sensome, the company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today enrollment of the first patients into a feasibility clinical study using the Clotild® Smart Guidewire in peripheral artery disease (PAD).
  • Clotild® was designated a breakthrough medical device for use in brain arteries by the FDA in 2021.
  • The clinical trial, named SEPARATE, is designed to assess the Clotild® sensor's capability to detect various characteristics of blood vessel blockages in PAD patients.
  • A key focus of the SEPARATE clinical trial is to evaluate the Clotild® sensor's capacity in differentiating between soft and friable "fresh" clots and organized "old" clots.